Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
Abstract Worldwide shortage of vaccination against SARS-CoV-2 infection while the pandemic is still uncontrolled leads many states to the dilemma whether or not to vaccinate previously infected persons. Understanding the level of protection of previous infection compared to that of vaccination is critical for policy making. We analyze an updated individual-level database of the entire population of Israel to assess the protection efficacy of both prior infection and vaccination in preventing subsequent SARS-CoV-2 infection, hospitalization with COVID-19, severe disease, and death due to COVID-19. Vaccination was highly effective with overall estimated efficacy for documented infection of 92·8% (CI:[92·6, 93·0]); hospitalization 94·2% (CI:[93·6, 94·7]); severe illness 94·4% (CI:[93·6, 95·0]); and death 93·7% (CI:[92·5, 94·7]). Similarly, the overall estimated level of protection from prior SARS-CoV-2 infection for documented infection is 94·8% (CI:[94·4, 95·1]); hospitalization 94·1% (CI:[91·9, 95·7]); and severe illness 96·4% (CI:[92·5, 98·3]). Our results question the need to vaccinate previously-infected individuals.
Mandel Micha、Goldberg Yair、Woodbridge Yonatan、Novikov Ilya、Yaari Rami、Freedman Laurence、Huppert Amit、Fluss Ronen、Ziv Arnona
The Hebrew University of JerusalemTechnion - Israel Institute of TechnologyThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical CenterThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical CenterThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical CenterThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical CenterThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center||Tel Aviv UniversityThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical CenterThe Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center
预防医学医学研究方法医药卫生理论
vaccine efficacyCOVID-19SARS-CoV-2previous infectionprotection from reinfection
Mandel Micha,Goldberg Yair,Woodbridge Yonatan,Novikov Ilya,Yaari Rami,Freedman Laurence,Huppert Amit,Fluss Ronen,Ziv Arnona.Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel[EB/OL].(2025-03-28)[2025-05-22].https://www.medrxiv.org/content/10.1101/2021.04.20.21255670.点此复制
评论